Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist

Background: The present study was undertaken mainly to investigate whether chemohormonal therapy with estramustine phosphate plus luteinizing hormone‐releasing hormone (LHRH) agonist has a more beneficial effect than the hormonal therapy with flutamide plus LHRH agonist for newly diagnosed patients...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of urology Vol. 11; no. 2; pp. 103 - 109
Main Authors:	NOGUCHI, MASANORI, NODA, SHINSHI, YOSHIDA, MASAKI, UEDA, SHOICHI, SHIRAISHI, TAIZO, ITOH, KYOGO
Format:	Journal Article
Language:	English
Published:	Melbourne, Australia Blackwell Publishing Ltd 01-02-2004
Subjects:	Aged Aged, 80 and over Androgen Antagonists - administration & dosage Antineoplastic Agents, Hormonal - administration & dosage chemotherapy Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination estramustine Estramustine - administration & dosage flutamide Flutamide - administration & dosage Gonadotropin-Releasing Hormone - antagonists & inhibitors Humans Male Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Probability Prognosis prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Survival Analysis Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!